These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29086638)

  • 21. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
    Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
    Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing the patent thicket and maximizing patent lifetime in vaccine technology.
    Mertes MM; Stötter G
    Hum Vaccin; 2010 Oct; 6(10):860-3. PubMed ID: 20948289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope-based approaches to a universal influenza vaccine.
    Gottlieb T; Ben-Yedidia T
    J Autoimmun; 2014 Nov; 54():15-20. PubMed ID: 25172355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
    Postma MJ; Milne G; Nelson EA; Pyenson B; Basili M; Coker R; Oxford J; Garrison LP;
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1431-9. PubMed ID: 21133667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens.
    Strecker T; Uhlendorff J; Diederich S; Lenz-Bauer C; Trusheim H; Roth B; Kolesnikova L; Aepinus C; Dornow R; Gerlach J; Matrosovich M; Valley U; Eickmann M; Becker S
    Clin Chem Lab Med; 2012 May; 50(7):1275-9. PubMed ID: 22850059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-voluntary licensing of antivirals under patent: options the Australian Government should consider in light of a potential bird flu pandemic.
    Davies T
    J Law Med; 2006 May; 13(4):479-95. PubMed ID: 16756217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic patent protection in the pharmaceutical and biotechnology industries.
    Nunnally AC; Webster CJ; Brown SA; Cohen GA
    Community Genet; 2005; 8(4):209-16. PubMed ID: 16244474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is Patent "Evergreening" Restricting Access to Medicine/Device Combination Products?
    Beall RF; Nickerson JW; Kaplan WA; Attaran A
    PLoS One; 2016; 11(2):e0148939. PubMed ID: 26910128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.
    Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
    Stittelaar KJ; Veldhuis Kroeze EJ; Rudenko L; Dhere R; Thirapakpoomanunt S; Kieny MP; Osterhaus AD
    Vaccine; 2011 Nov; 29(49):9265-70. PubMed ID: 21945964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets.
    Partridge J; Kieny MP;
    Vaccine; 2010 Jul; 28(30):4709-12. PubMed ID: 20488262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summoning a New Artificial Intelligence Patent Model: In The Age Of Pandemic.
    Yanisky-Ravid S; Jin R
    SSRN; 2020 Jun; ():3619069. PubMed ID: 32714121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.